For Immediate Release
Chicago, IL – June 1, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (
MRK Quick Quote MRK - Free Report) , Glaxo ( GSK Quick Quote GSK - Free Report) , Roche ( RHHBY Quick Quote RHHBY - Free Report) , Sanofi ( SNY Quick Quote SNY - Free Report) , Bristol-Myers ( BMY Quick Quote BMY - Free Report) . Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Coronavirus Vaccine Edition
This week, Merck, Glaxo and Roche made announcements related to their efforts to make vaccines and medicines for COVID-19. Sanofi announced its intention to sell majority of its stake in Regeneron through a registered public offering and share buyback by Regeneron. The FDA granted approvals to Bristol-Myers’ dual immunotherapy, Opdivo + Yervoy for a new lung cancer indication and Sanofi’s Dupixent to treat atopic dermatitis or eczema in kids.
Recap of the Week’s Most Important Stories: Merck announced Merck Enters COVID-19 Vaccine/Treatment Development Arena: three deals to find new medicines and vaccines to help combat COVID-19. First, Merck announced a deal to acquire Austrian private biotech, Themis, which has a COVID-19 vaccine candidate in preclinical development. Themis developed the candidate using its measles virus vector platform. Second, Merck is buying exclusive worldwide rights to develop and commercialize private biotech Ridgeback Biotherapeutics’ oral antiviral candidate, EIDD-2801, which is being evaluated in early clinical studies to treat COVID-19.
Merck will take care of clinical development and regulatory filings of the candidate. Third, Merck signed a collaboration with a non-profit research organization, IAVI to co-develop a vaccine to prevent COVID-19.
: Glaxo said it plans to produce 1 billion doses of its pandemic vaccine adjuvant next year to support the development of multiple COVID-19 vaccine candidates that are suitable for use with an adjuvant. The pandemic adjuvant can reduce the amount of vaccine protein required per dose, which can result in production of more vaccines. Glaxo has formed several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates. Glaxo to Make 1B Doses of its Adjuvanted COVID-19 Vaccine
Meanwhile, the FDA granted priority review designation to Glaxo’s regulatory application seeking approval of its drug Nucala for Hypereosinophilic Syndrome (HES), a rare disease caused by eosinophilic inflammation. Nucala is already marketed for severe eosinophilic asthma and for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).
Roche, in partnership with Gilead, initiated a phase III study to evaluate its drug Actemra/RoActemra plus Gilead’s antiviral remdesivir in hospitalized patients with severe COVID-19 pneumonia. Remdesivir is already being evaluated in phase III studies as a monotherapy for the treatment of COVID-19. Meanwhile, Roche is also evaluating Actemra in a phase III study in hospitalized patients with severe COVID-19 pneumonia. Roche is close to completing enrollment in this study with data expected to be presented this summer. Roche Begins Study on Actemra plus Gilead’s Remdesivir in Severe COVID-19 Patients: Sanofi intends to Sanofi to Exit Most of Its Stake in Regeneron: sell most of its stake in Regeneron through a registered public offering and related share repurchase by Regeneron. Sanofi currently holds approximately 23.2 million shares of Regeneron common stock, which represents approximately 20.6% ownership. Sanofi plans to sell a portion of its stake (almost worth $7.3 billion) in Regeneron through a registered public offering.
Regeneron will thereafter repurchase its common stock worth $5 billion from Sanofi, following the successful completion of the public offer. Following the completion of public offering and share repurchase, Sanofi will continue to hold approximately 400,000 shares of Regeneron. However, the deal will have no effect on the companies’ ongoing collaboration terms.
Meanwhile, Dupixent’s pivotal phase III study evaluating it in patients 12 years and older with eosinophilic esophagitis (EoE) met both its co-primary endpoints, as well as all key secondary endpoints. In the study, Dupixent dramatically reduced eosinophils in the esophagus and also improved all clinical, anatomic and histologic measures of the disease.
The FDA granted approval to Bristol-Myers dual immunotherapy, Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. The FDA approval was based on pre-specified interim data from the phase III CheckMate -9LA study. Several Approvals by FDA and EC:
This marks the second approval of an Opdivo + Yervoy-based combo for the first-line treatment of advanced NSCLC. Last week, the FDA had approved Opdivo + Yervoy as first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1≥1%.
The FDA approved Sanofi/Regeneron’s blockbuster drug,
Dupixent to treat children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is notwell controlled on topical prescription medications. Dupixent is already approved to treat moderate-to-severe atopic dermatitis in adults as well as for two other type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis and severe asthma.
Meanwhile, the European Commission approved Bristol-Myers’ Zeposia (ozanimod) for treating relapsing remitting multiple sclerosis (RRMS) patients with active disease. With the approval, Zeposia becomes a new first-line treatment option in Europe, which can help address the disease’s hallmark relapses and brain lesions.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.